References

ACOG., 2009. Hereditary breast and ovarian cancer syndrome. American College of Obstetricians and Gynecologists (ACOG), Washington, DC., ACOG Practice Bulletin no. 103).http://www.guidelines.gov/content.aspx?id=14336.

Antoniou, A., P.D.P. Pharoah, S. Narod, H.A. Risch and J.E. Eyfjord et al., 2003. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: A combined analysis of 22 studies. Am. J. Hum. Genet., 72: 1117-1130.
CrossRef  |  

Brohet, R.M., D.E. Goldgar, D.F. Easton, A.C. Antoniou and N. Andrieu et al., 2007. Oral contraceptives and breast cancer risk in the international BRCA1/2 carrier cohort study: A report from EMBRACE, GENEPSO, GEOHEBON and the IBCCS Collaborating Group. J. Clin. Oncol., 25: 3831-3836.
Direct Link  |  

Burke, W., M. Daly, J. Garber, Botkin and M.J. Kahn et al., 1997. Recommendations for follow-up care of individuals with an inherited predisposition to cancer. II. BRCA1 and BRCA2. cancer genetics studies consortium. JAMA, 277: 997-1003.
PubMed  |  

Dowdy, S.C., M. Stefanek and L.C. Hartmann, 2004. Surgical risk reduction: Prophylactic salpingo-oophorectomy and prophylactic mastectomy. Am. J. Obstet. Gynecol., 191: 1113-1123.
PubMed  |  

Finch, A., M. Beiner, J. Lubinski, H.T. Lynch and P. Moller et al., 2006. Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 Mutation. JAMA, 296: 185-192.
Direct Link  |  

Kauff, N.D., N. Mitra, M.E. Robson, K.E. Hurley and S. Chuai et al., 2005. Risk of ovarian cancer in BRCA1 and BRCA2 mutation-negative hereditary breast cancer families. J. Natl Cancer Inst., 97: 1382-1384.
CrossRef  |  

Kauff, N.D., S.M. Domchek, T.M. Friebel, M.E. Robson and J. Lee et al., 2008. Risk-reducing salpingo-oophorectomy for the prevention of BRCA1 and BRCA2 associated breast and gynecologic cancer: A multicenter, prospective study. J. Clin. Oncol., 26: 1331-1337.
PubMed  |  

King, M.C., J.H. Marks and J.B. Mandell, 2003. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science, 302: 643-646.
PubMed  |  

King, M.C., S. Wieand, K. Hale, M. Lee and T. Walsh et al., 2001. Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National surgical adjuvant breast and bowel project (NSABP-P1) breast cancer prevention trial. JAMA, 286: 2251-2256.
PubMed  |  

Metcalfe, K.A., H.T. Lynch, P. Ghadirian, N. Tung and I.A. Olivotto et al., 2005. The risk of ovarian cancer after breast cancer in BRCA1 and BRCA2 carriers. Gynecol. Oncol., 96: 222-226.
PubMed  |  

Modan, B., P. Hartge, G. Hirsh-Yechezkel, A. Chetrit and F. Lubin et al., 2001. Parity, oral contraceptives and the risk of ovarian cancer among carriers and noncarriers of a BRCA1 or BRCA2 mutation. N. Engl. J. Med., 345: 235-4230.
Direct Link  |  

NCCN., 2009. Genetic/familial high-risk assessment: Breast and ovarian. NCCN Clinical Practice Guidelines in Oncology, NCCN Clinical Practice Guidelines in Oncology, http://hematoncoearchive.com/guidelines/NCCN%20Guidelines_Detection_Prevention_Risk%20Reduction/genetics_screening.pdf.

Risch, H.A., J.R. McLaughlin, D.E. Cole, B. Rosen, L. Bradley and I. Fan et al., 2006.. Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: A kin-cohort study in Ontario, Canada. J. Natl Cancer Inst, 98: 1694-1706.
PubMed  |  

Rodriquez, E. and S.M. Domchek, 2007. The prevention of hereditary breast cancer. Semin. Oncol., 34: 401-405.
CrossRef  |  PubMed  |  

Walsh, T., S. Casadei, K.H. Coats, E. Swisher and S.M. Stray et al., 2006. Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer. JAMA, 295: 1379-1388.
CrossRef  |  

Whittemore, A.S., G. Gong and J. Itnyre, 1997. Prevalence and contribution of BRCA1 mutations in breast cancer and ovarian cancer: Results from three U.S. population-based case- control studies of ovarian cancer. Am. J. Hum. Genet., 60: 496-504.
Direct Link  |